Google
Trusted Resources: News & Events
Latest announcements and gatherings
Emmaus Life Sciences Launches Its Commercial Co-Payment Assistance Program for Endari™
Emmaus Life Sciences, Inc., a leader in sickle cell disease treatment, announced today that it will provide financial assistance to help eligible patients afford their monthly co-payment for Endari™ (L-glutamine oral powder)1. The program is limited to financially eligible patients covered by commercial insurance.
A significant number of individuals with sickle cell disease are covered by commercial insurance. In some cases, patients may have difficulty affording the monthly co-payment amount.
Mark Diamond, Emmaus’ Vice President of Commercialization, commented: “We are committed to removing barriers between patients and Endari – giving a greater number of patients access to our effective treatment for sickle cell disease.”
+myBinderRelated Content
-
Hemoglobinopathy Counselor Training Course – VIRTUALUPDATE! 2020 Hemoglobinopathy Counselor ...
-
Global HOPE Initiative Plans $100M Pediatric Hematology-Oncology Treatment Network in AfricaThe Bristol-Myers Squibb Foundation, Tex...
-
Foundation For Sickle Cell Disease ResearchThe Foundation for Sickle Cell Disease R...
-
Sickle Cell Disease Association of Alabama – Mobile ChapterThe Sickle Cell Disease Association of A...
-
In Support of Rare Disease Patients Impacted by COVID-19, NORD Launches Premium and Limited Medical Relief ProgramUnited with more than 25 million America...
-
The Valerie FundThe Valerie Fund has pediatric sickle ce...
-
Too many children live too far from sickle cell treatment they needBack in September, the fuel pump on Cynt...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.